Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.69 |
| ▸ | BLM | P54132 | 4/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | APEX1 | P27695 | 2/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.69 |
| ▸ | USP2 | O75604 | 2/20 | 0.69 |
| ▸ | EGFR | P00533 | 2/20 | 0.69 |
| ▸ | FYN | P06241 | 2/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.69 |
| ▸ | RECQL | P46063 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1485974 | 1.00 | HSD17B10 (0.69) | HSD17B10KDM4EMAPTHPGDALDH1A1 | |
| SCHEMBL29881847 | 1.00 | HSD17B10 (0.69) | HSD17B10KDM4EMAPTHPGDALDH1A1 | |
| SCHEMBL30002544 | 0.87 | KDM4E (0.52) | HSD17B10KDM4EMAPTHPGDALDH1A1 | |
| SCHEMBL24761175 | 0.86 | KDM4E (0.68) | HSD17B10KDM4EMAPTHPGDALDH1A1 | |
| Methyldopate SCHEMBL297359 | 0.85 | HSD17B10 (0.66) | HSD17B10KDM4EMAPTHPGDALDH1A1 | |
| Methyldopate SCHEMBL11430187 | 0.85 | HSD17B10 (0.66) | HSD17B10KDM4EMAPTHPGDALDH1A1 | |
| Methyldopate SCHEMBL29587132 | 0.85 | HSD17B10 (0.66) | HSD17B10KDM4EMAPTHPGDALDH1A1 | |
| Hydrochloric Acid SCHEMBL28027363 | 0.84 | KDM4E (0.56) | HSD17B10KDM4EMAPTHPGDALDH1A1 | |
| SCHEMBL11850560 | 0.84 | KDM4E (0.61) | HSD17B10KDM4EMAPTHPGDALDH1A1 | |
| SCHEMBL24761068 | 0.84 | KDM4E (0.64) | HSD17B10KDM4EMAPTHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193209-A1 | A POLYMER PRODUCT AND PREPARATION THEROF | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2018-07-12 | — | — | US | claimed |
| EP-3319779-A1 | A POLYMER PRODUCT AND PREPARATION THEREOF | Singapore Health Services Pte Ltd (SG) | 2018-05-16 | — | — | EP | claimed |
| US-20110136704-A1 | Methods of Treating a Hydrocarbon-Bearing Formation, a Well Bore, and Particles | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-06-09 | — | — | US | claimed |
| EP-2300558-A2 | METHODS OF TREATING A HYDROCARBON-BEARING FORMATION, A WELL BORE, AND PARTICLES | Board of Regents, The University of Texas System (US) | 2011-03-30 | — | — | EP | claimed |
| WO-2009148831-A2 | METHODS OF TREATING A HYDROCARBON-BEARING FORMATION, A WELL BORE, AND PARTICLES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-12-10 | — | — | WO | claimed |
| EP-4731266-A1 | NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES | The Regents of the University of Michigan (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250325644-A1 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | ELICIO THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4627079-A2 | THERMOSTABLE BINDING SCAFFOLDS | Nectagen, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2007042848-A2 | PROCESS FOR THE PREPARATION OF CARBIDOPA | EGIS GYÓGYSZERGYÁR (HU) | 2007-04-19 | — | — | WO | disclosed |
| EP-0821551-B1 | SCREENING ASSAY FOR THE IDENTIFICATION OF INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | PICOWER INST MED RES (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030105014-A1 | Preparing reaction mixture of macrophage migration inhibitory factor(MIF) and MIF-substrate in the presence and absence of a test compound; detecting tautomerization of the MIF- substrate | CYTOKINE PHARMASCIENCES, INC. | 2003-06-05 | — | — | US | disclosed |
| US-6420188-B1 | KITS FOR USE IN MONITORING CYTOKINE-MEDIATED TOXICITY, SHOCK, INFLAMMATION, GRAFT-VERSUS-HOST DISEASE, AND AUTOIMMUNE DISEASES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2002-07-16 | — | — | US | disclosed |
| EP-0821551-A4 | SCREENING ASSAY FOR THE IDENTIFICATION OF INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | PICOWER INST MED RES (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-0821551-A1 | SCREENING ASSAY FOR THE IDENTIFICATION OF INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1997029635-A1 | SCREENING ASSAY FOR THE IDENTIFICATION OF INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-08-21 | — | — | WO | disclosed |
| US-4087520-A | Lowering blood pressure with new L-3-(3,4-dihydroxyphenyl)-2-methyl-alanine peptides | BOEHRINGER MANNHEIM GMBH (DT) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105014-A1 | Preparing reaction mixture of macrophage migration inhibitory factor(MIF) and MIF-substrate in the presence and absence of a test compound; detecting tautomerization of the MIF- substrate | MIF, DDT, COMT | HSD17B10 421/4885KDM4E 3305/4885MAPT 601/4885 |
| US-12427200-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | HSD17B10 4645/4885KDM4E 4753/4885MAPT 2394/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | HSD17B10 4780/4885KDM4E 1225/4885MAPT 1974/4885 |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | ALB, FCGR3B, FCGR1A | HSD17B10 4784/4885KDM4E 1470/4885MAPT 2428/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | HSD17B10 2909/4885KDM4E 1204/4885MAPT 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.